咖啡因摄入与痴呆:路易体是关联所在吗?
研究纳入Rush记忆与衰老项目888名59岁以上参与者及英国生物银行303887名55岁以上参与者,分析咖啡因摄入与认知障碍的关联。MAP中咖啡因摄入>100 mg/天与全因痴呆(HR=1.35,95%CI=1.03-1.76)和阿尔茨海默病痴呆(HR=1.41,95%CI=1.07-1.85)风险升高相关;UKB中每日100-400 mg咖啡因与全因痴呆风险降低相关。MAP中咖啡因摄入与死后路易体呈负相关,>100 mg/天与新皮质型路易体减少相关(OR=0.40,95%CI=0.21-0.75)。
要点
- MAP中咖啡因摄入>100 mg/天与全因痴呆(HR=1.35)和AD痴呆(HR=1.41)风险升高相关。
- UKB中每日100-400 mg咖啡因与全因痴呆风险降低相关,>400 mg/天无显著关联。
- MAP中咖啡因摄入>100 mg/天与新皮质型路易体减少相关(OR=0.40)。
核心结论
- 咖啡因摄入与临床痴呆的关联不一致,可能由队列间潜在痴呆病因学差异解释。
- 路易体可能将咖啡因与部分人群的较低风险联系起来。
研究设计与样本
- 研究纳入Rush记忆与衰老项目(MAP)888名59岁以上参与者和英国生物银行(UKB)303887名55岁以上参与者。
- MAP参与者每年接受认知测试,痴呆诊断基于临床神经学检查和标准化标准,部分提供死后组织进行神经病理评估。
- UKB中痴呆由关联的医院和死亡记录确定,两队列均使用食物频率问卷估计自我报告的咖啡因摄入。
- 采用Cox比例风险比(HR)、回归和混合模型分析咖啡因摄入与 incident dementia、认知下降和神经病理的关联。
主要发现
- MAP中,与≤100 mg/天相比,咖啡因摄入>100 mg/天与全因痴呆(HR=1.35,95%CI=1.03-1.76)和AD痴呆(HR=1.41,95%CI=1.07-1.85)风险升高显著相关。
- MAP中咖啡因摄入与认知下降无关联。
- UKB中,与≤100 mg/天相比,每日100≤200、200≤300、300≤400和>400 mg咖啡因的全因痴呆HR(95%CI)分别为0.83(0.72-0.94)、0.74(0.64-0.85)、0.74(0.64-0.85)和0.92(0.79-1.08);阿尔茨海默病痴呆结果类似。
- MAP中咖啡因摄入与死后路易体呈负相关,但与其他年龄相关病理无关联;>100 mg/天与新皮质型路易体减少相关(OR=0.40,95%CI=0.21-0.75)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: The objective of this study was to examine the association between caffeine intake and cognitive impairment. Caffeine-neuropathology correlations and interactions with lifestyle and genetic factors impacting caffeine metabolism and response were also tested. METHODS: We included 888 participants aged 59+ years from the Rush Memory and Aging Project (MAP) and 303,887 participants aged 55+ years from the UK Biobank (UKB). MAP participants took part in annual cognitive testing. Diagnosis of dementia was based on clinical neurological examination and standardized criteria. A subset provided postmortem tissue for neuropathologic evaluation for common age-related diseases (eg, Alzheimer's disease [AD], Lewy bodies, and vascular). For UKB, dementia was determined by linked hospital and death records. Self-reported caffeine intake was estimated using food-frequency questionnaires in both cohorts. Cox proportional hazard ratio (HR), regression, and mixed models were used to examine associations of caffeine intake with incident dementia, cognitive decline, and neuropathology. RESULTS: In MAP, compared to ≤100 mg/day, caffeine intake >100 mg/day was associated with a significantly higher HR (95% confidence interval [CI]) of all-cause (HR = 1.35, 95% CI = 1.03-1.76) and AD (HR = 1.41, 95% CI = 1.07-1.85) dementia. Caffeine intake was not associated with cognitive decline. In UKB, compared to ≤100 mg/day, the HRs (95% CI) of all-cause dementia for consuming 100 ≤ 200, 200 ≤ 300, 300 ≤ 400, and > 400 mg/day were 0.83 (95% CI = 0.72-0.94), 0.74 (95% CI = 0.64-0.85), 0.74 (95% CI = 0.64-0.85), and 0.92 (95% CI = 0.79-1.08), respectively. Similar results were observed for Alzheimer's dementia. In MAP, caffeine intake was inversely associated with postmortem Lewy bodies but no other age-related pathologies. Caffeine intake >100 mg/day was associated with lower neocortical type Lewy bodies (odds ratio (95%CI): 0.40 (95% CI = 0.21-0.75). INTERPRETATION: Caffeine intake was inconsistently associated with clinical dementia; potentially explained by cohort differences in underlying dementia etiology. Lewy bodies may link caffeine to lower risk in some persons. ANN NEUROL 2022;91:834-846.
引用
- Cornelis MC, Bennett DA, Weintraub S, et al. Caffeine Consumption and Dementia: Are Lewy Bodies the Link? Ann Neurol. 2022. PMID: 35288978. doi:10.1002/ana.26349
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。